Predictive value of SLCO1B1 c.521T>C polymorphism on observed changes in the treatment of 1136 statin-users

Autor: Marleen E. Jansen, Tessel Rigter, Thom M. C. Fleur, Patrick C. Souverein, W. M. Monique Verschuren, Susanne J. Vijverberg, Jesse J. Swen, Wendy Rodenburg, Martina C. Cornel
Přispěvatelé: Human genetics, APH - Quality of Care, APH - Personalized Medicine, Amsterdam Reproduction & Development (AR&D)
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Genes, 14(2). MDPI
Genes, 14(2):456. Multidisciplinary Digital Publishing Institute (MDPI)
Genes
Volume 14
Issue 2
Pages: 456
Jansen, M E, Rigter, T, Fleur, T M C, Souverein, P C, Verschuren, W M M, Vijverberg, S J, Swen, J J, Rodenburg, W & Cornel, M C 2023, ' Predictive Value of SLCO1B1 c.521T >C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users ', Genes, vol. 14, no. 2, 456 . https://doi.org/10.3390/genes14020456
ISSN: 2073-4425
DOI: 10.3390/genes14020456
Popis: Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with SLCO1B1 c.521T>C as a risk factor for statin-induced adverse drug reactions. The focus was on changes in therapy as a proxy for adverse drug reactions observed in statin-users in a population-based Dutch cohort. In total, 1136 statin users were retrospectively genotyped for the SLCO1B1 c.521T>C polymorphism (rs4149056) and information on their statin dispensing was evaluated as cross-sectional research. Approximately half of the included participants discontinued or switched their statin treatment within three years. In our analyses, we could not confirm an association between the SLCO1B1 c.521T>C genotype and any change in statin therapy or arriving at a stable dose sooner in primary care. To be able to evaluate the predictive values of SLCO1B1 c.521T>C genotype on adverse drug reactions from statins, prospective data collection of actual adverse drug reactions and reasons to change statin treatment should be facilitated.
Databáze: OpenAIRE
Externí odkaz: